Abstract
Guillain–Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy, and pathophysiologically classified into acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and acute motor and sensory axonal neuropathy (AMSAN). The main pathophysiological mechanism is complement-mediated nerve injury caused by antibody–antigen interaction in the peripheral nerves. Antiglycolipid antibodies are most pathogenic factors in the development of GBS, but not found in 40% of patients with GBS. One of the principal target regions in GBS is the node of Ranvier where functional molecules including glycolipids are assembled. Nodal dysfunction induced by the immune response in nodal axolemma, termed “nodopathy,” can electrophysiologically show reversible conduction failure, axonal degeneration, or segmental demyelination. To detect new target molecules in antiglycolipid antibody-negative GBS and to elucidate the pathophysiology in the subacute and the subsequent phases of the disorder are the next problems.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cornblath DR, Griffin DE, Welch D et al (1990) Quantitative analysis of endoneurial T-cells in human sural nerve biopsies. J Neuroimmunol 26:113–118
Doppler K, Appeltshauser L, Villmann C et al (2016) Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain 139:2617–2630
Feasby TE, Gilbert JJ, Brown WF et al (1986) An acute axonal form of Guillain-Barré polyneuropathy. Brain 109:1115–1126
Feasby TE, Hahn AF, Brown WF et al (1993) Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms? J Neurol Sci 116:185–192
Fehmi J, Scherer SS, Willison HJ et al (2018) Nodes, paranodes and neuropathies. J Neurol Neurosurg Psychiatry 89:61–71. https://doi.org/10.1136/jnnp-2016-315480
Fujioka T (2018) Experimental autoimmune neuritis. Clin Exp Neuroimmunol 9:84–92. https://doi.org/10.1111/cen3.12461
Griffin JW, Sheikh K (2005) The Guillain-Barré syndromes. In: Thomas PK, Dyck PJ (eds) Peripheral neuropathy, 4th edn. Elsevier Saunders, Philadelphia, PA, pp 2197–2219
Griffin JW, Li CY, Ho TW et al (1995) Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain 118:577–595
Griffin JW, Li CY, Ho TW et al (1996a) Pathology of the motor sensory axonal Guillain-Barré syndrome. Ann Neurol 39:17–28. https://doi.org/10.1002/ana.410390105
Griffin JW, Li CY, Macko C et al (1996b) Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 25:33–51
Hafer-Macko CE, Sheikh KA, Li CY et al (1996a) Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 39:625–635. https://doi.org/10.1002/ana.410390512
Hafer-Macko C, Hsieh ST, Li CY et al (1996b) Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 40:635–644. https://doi.org/10.1002/ana.410400414
Halstead SK, Zitman FM, Humphreys PD et al (2008) Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 131:1197–1208. https://doi.org/10.1093/brain/awm316
Haymaker WE, Kernohan JW (1949) The Landry-Guillain-Barré syndrome; a clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine 28:59–141
He L, Zhang G, Liu W et al (2015) Anti-ganglioside antibodies induce nodal and axonal injury via Fcc receptor-mediated inflammation. J Neurosci 35:6770–6785. https://doi.org/10.1523/JNEUROSCI.4926-14.2015
Ho TW, Hsieh ST, Nachamkin I et al (1997) Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 48:717–724
Kalimo H, Molnár GK, Saksa M et al (1982) Involvement of autonomic nervous system in experimental allergic neuritis. A light- and electron-microscopic study. J Neuroimmunol 2:9–19
Kanda T, Hayashi H, Tanabe H et al (1989) A fulminant case of Guillain-Barré syndrome: topographic and fibre size related analysis of demyelinating changes. J Neurol Neurosurg Psychiatry 52:857–864
Kuwabara S, Asahina M, Koga M et al (1998a) Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody. Neurology 51:1656–1660
Kuwabara S, Yuki N, Koga M et al (1998b) IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 44:202–208. https://doi.org/10.1002/ana.410440210
Kuwahara M, Suzuki S, Takada K et al (2011) Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 239:87–90. https://doi.org/10.1016/j.jneuroim.2011.08.016
Matsuyama H, Haymaker W (1967) Distribution of lesions in the Landry-Guillain-Barré syndrome, with emphasis on involvement of the sympathetic system. Acta Neuropathol 8:230–241
McKhann GM, Cornblath DR, Griffin JW et al (1993) Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 33:333–342. https://doi.org/10.1002/ana.410330402
Misawa S, Kuwabara S, Sato Y et al (2018) Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol 17:519–529. https://doi.org/10.1016/S1474-4422(18)30114-5
Mitchell PL, Meilman E (1967) The mechanism of hypertension in the Guillain-Barré syndrome. Am J Med 42:986–995
Morey MK, Wiley CA, Hughes RA et al (1985) Autonomic nerves in experimental allergic neuritis in the rat. Acta Neuropathol 67:75–80
Ng JK, Malotka J, Kawakami N et al (2012) Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 79:2241–2248
Saida T, Saida K, Dorfman SH et al (1979) Experimental allergic neuritis induced by sensitization with galactocerebroside. Science 204:1103–1106
Samukawa M, Hamada Y, Kuwahara M et al (2014) Clinical features in Guillain-Barré syndrome with anti-Gal-C antibody. J Neurol Sci 337:55–60. https://doi.org/10.1016/j.jns.2013.11.016
Samukawa M, Kuwahara M, Morikawa M et al (2016) Electrophysiological assessment of Guillain-Barré syndrome with both Gal-C and ganglioside antibodies; tendency for demyelinating type. J Neuroimmunol 301:61–64. https://doi.org/10.1016/j.jneuroim.2016.10.006
Sawai S, Satoh M, Mori M et al (2014) Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. Neurology 83:113–117. https://doi.org/10.1212/WNL.0000000000000566
Sobue G, Li M, Terao S et al (1997) Axonal pathology in Japanese Guillain-Barré syndrome: a study of 15 autopsied cases. Neurology 48:1694–1700
Solders G, Persson A, Kristensson K et al (1985) Autonomic dysfunction in experimental allergic neuritis. Acta Neurol Scand 72:18–25
Susuki K (2016) Node of Ranvier disruption in Guillain–Barré syndrome. Clin Exp Neuroimmunol 7:324–329. https://doi.org/10.1111/cen3.12338
Susuki K, Rasband MN, Tohyama K et al (2007) Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 27:3956–3967. https://doi.org/10.1523/JNEUROSCI.4401-06.2007
Susuki K, Yuki N, Schafer DP et al (2012) Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 233:534–542. https://doi.org/10.1016/j.expneurol.2011.11.039
Takada K, Shimizu J, Kusunoki S (2008) Apoptosis of primary sensory neurons in GD1b-induced sensory ataxic neuropathy. Exp Neurol 209:279–283. https://doi.org/10.1016/j.expneurol.2007.09.010
Ueda A, Shima S, Miyashita T et al (2010) Anti-GM1 antibodies affect the integrity of lipid rafts. Mol Cell Neurosci 45:355–362. https://doi.org/10.1016/j.mcn.2010.07.008
Uncini A, Kuwabara S (2015) Nodopathies of the peripheral nerve: an emerging concept. J Neurol Neurosurg Psychiatry 86:1186–1195. https://doi.org/10.1136/jnnp-2014-310097
Uncini A, Vallat JM (2018) Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground. J Neurol Neurosurg Psychiatry 89:627–635. https://doi.org/10.1136/jnnp-2017-317192
Wanschitz J, Maier H, Lassmann H et al (2003) Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome. Brain 126:2034–2042. https://doi.org/10.1093/brain/awg207
Yako K, Kusunoki S, Kanazawa I (1999) Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain-Barré syndrome. J Neurol Sci 168:85–89
Yuki N, Hartung HP (2012) Guillain-Barré Syndrome. N Engl J Med 366:2294–2304. https://doi.org/10.1056/NEJMra1114525
Yuki N, Susuki K, Koga M et al (2004) Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A 101:11404–11409. https://doi.org/10.1073/pnas.0402391101
Zochodne DW (1994) Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve 17:1145–1155. https://doi.org/10.1002/mus.880171004
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Kaida, K. (2019). Guillain–Barré Syndrome. In: Sango, K., Yamauchi, J., Ogata, T., Susuki, K. (eds) Myelin. Advances in Experimental Medicine and Biology, vol 1190. Springer, Singapore. https://doi.org/10.1007/978-981-32-9636-7_20
Download citation
DOI: https://doi.org/10.1007/978-981-32-9636-7_20
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9635-0
Online ISBN: 978-981-32-9636-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)